Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study demonstrated that inflammation signaling from multiple pathogens, including Influenza A, coronavirus, and a common bacterium (H. influenzae), was inhibited by Edesa's TLR4 antagonist, paridiprubart. These findings support the potential expanded uses for paridiprubart in treating Acute Respiratory Distress Syndrome (ARDS) caused by coronaviruses, pandemic influenza, and harmful bacteria.
Paridiprubart belongs to a new class of therapies called Host-Directed Therapeutics (HDTs), which modulate the body's immune response to infectious diseases. These therapies have the potential to work across multiple infectious diseases and could be stockpiled preemptively ahead of outbreaks.
The University of Toronto conducted the in vitro study in collaboration with Edesa Biotech under a grant from the Government of Canada's Strategic Innovation Fund. The research results are available in a preprint manuscript published at bioRxiv.org